GeneOne Life Science Inc (011000) — Cash Flow-to-Debt Ratio
GeneOne Life Science Inc (011000) has a Cash Flow-to-Debt Ratio of -0.02x as of December 2025, meaning its operating cash flow of ₩-1.77 Billion could theoretically repay 0% of its total liabilities (₩78.31 Billion) in one year. Explore 011000 long-term investments to assets to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
GeneOne Life Science Inc Cash Flow-to-Debt Ratio (2013–2025)
Historical debt coverage capacity for GeneOne Life Science Inc across 13 annual periods. Also explore 011000 total asset value for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for GeneOne Life Science Inc (2013–2025)
Year-by-year debt coverage analysis for GeneOne Life Science Inc. For market capitalisation and broader financial context, see how much is GeneOne Life Science Inc worth.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.21x | ₩-16.54 Billion | ₩78.31 Billion | ▲ +13.5% |
| 2024 | -0.24x | ₩-16.06 Billion | ₩65.73 Billion | ▲ +55.6% |
| 2023 | -0.55x | ₩-21.74 Billion | ₩39.52 Billion | ▲ +5.5% |
| 2022 | -0.58x | ₩-24.11 Billion | ₩41.40 Billion | ▼ -429.0% |
| 2021 | -0.11x | ₩-4.85 Billion | ₩44.04 Billion | ▲ +73.7% |
| 2020 | -0.42x | ₩-15.92 Billion | ₩38.06 Billion | ▼ -792.0% |
| 2019 | -0.05x | ₩-1.27 Billion | ₩27.09 Billion | ▲ +87.2% |
| 2018 | -0.37x | ₩-7.27 Billion | ₩19.89 Billion | ▲ +17.7% |
| 2017 | -0.44x | ₩-4.04 Billion | ₩9.09 Billion | ▼ -6.9% |
| 2016 | -0.42x | ₩-12.39 Billion | ₩29.81 Billion | ▼ -540.5% |
| 2015 | 0.09x | ₩778.50 Million | ₩8.25 Billion | ▲ +113.7% |
| 2014 | -0.69x | ₩-4.16 Billion | ₩6.03 Billion | ▼ -138.1% |
| 2013 | -0.29x | ₩-2.35 Billion | ₩8.11 Billion | — |